Ph.D. Program in Biomedical Engineering, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
Department of Orthopedics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
Medicina (Kaunas). 2022 Aug 1;58(8):1028. doi: 10.3390/medicina58081028.
: For the treatment of knee osteoarthritis (OA), intra-articular platelet-rich plasma (PRP) and novel crosslinked single-dose hyaluronic acid (HA) have both been reported to improve outcomes, but no study has compared them for the treatment of knee OA. We hypothesized patients with early-stage knee OA who received PRP injections would have more WOMAC score changes than those who received HA injections. This is the first prospective, double-blind, parallel, randomized controlled trial comparing the efficacy of intra-articular single-dose PRP versus novel crosslinked HA (HyajointPlus) for treating early-stage knee OA. : This study analyzed 110 patients randomized into the PRP ( = 54) or HA ( = 56) groups. The primary outcome is the change of WOMAC score at 1-, 3-, and 6-month follow-ups compared to baseline. : The data revealed significant improvements in all WOMAC scores in the PRP group at 1-, 3-, and 6-month follow-up visits compared with the baseline level except for the WOMAC stiffness score at the 1-month follow up. In the HA group, significant improvements were observed only in the WOMAC pain score for all the follow-up visits and in WOMAC stiffness, function, and total scores at 6-month follow-up. When comparing the change of WOMAC score at 1-, 3-, and 6-month follow-ups, no significant differences were found between PRP and HA group. : This study revealed that both PRP and HA can yield significant improvements in WOMAC scores at 6-month follow-up without any between-group differences at 1-, 3-, and 6-month follow-ups. Thus, both the single-injection regimens of PRP and HA can improve the functional outcomes for treating early-stage knee OA.
对于膝骨关节炎(OA)的治疗,关节内富血小板血浆(PRP)和新型交联单剂量透明质酸(HA)均已被报道可改善结局,但尚无研究比较它们治疗膝 OA 的效果。我们假设接受 PRP 注射的早期膝 OA 患者的 WOMAC 评分变化会比接受 HA 注射的患者更多。这是首例前瞻性、双盲、平行、随机对照试验,比较了关节内单次 PRP 与新型交联 HA(HyajointPlus)治疗早期膝 OA 的疗效。
这项研究分析了 110 例随机分为 PRP(n = 54)或 HA(n = 56)组的患者。主要结局是与基线相比,1、3 和 6 个月随访时 WOMAC 评分的变化。
数据显示,PRP 组在 1、3 和 6 个月随访时,除 1 个月随访时的 WOMAC 僵硬评分外,所有 WOMAC 评分均显著改善,而 HA 组仅在所有随访时的 WOMAC 疼痛评分以及在 6 个月随访时的 WOMAC 僵硬、功能和总分显著改善。比较 1、3 和 6 个月随访时 WOMAC 评分的变化,PRP 和 HA 组之间无显著差异。
本研究表明,PRP 和 HA 均可在 6 个月随访时显著改善 WOMAC 评分,而在 1、3 和 6 个月随访时两组间无差异。因此,PRP 和 HA 的单次注射方案均可改善早期膝 OA 的功能结局。